Navigation Links
PARP inhibitors may have clinical utility in HER2-positive breast cancers
Date:9/16/2012

PHILADELPHIA Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

Currently, women with HER2-positive breast cancers are treated with therapies that target HER2. However, many women with this form of cancer either fail to ever respond to these targeted therapies or initially respond to them but then become resistant to their effects.

"Until now, PARP inhibitors have been shown to exhibit single agent activity only in tumors that are deficient in DNA repair, such as familial breast and ovarian cancers that are linked to BRCA mutations," said Eddy S. Yang, M.D., Ph.D., assistant professor in the department of radiation oncology at the University of Alabama-Birmingham.

According to Yang, only about 5 to 10 percent of all breast and ovarian cancers are BRCA-associated familial cancers, so researchers are currently trying to expand the patient population that might benefit from PARP inhibitors, which are generally well tolerated and have relatively few side effects.

"To do that, we were attempting to render nonfamilial cancers deficient in DNA repair," he said.

In prior studies, the Yang lab found that inhibiting the epidermal growth factor receptor (EGFR) pathway, which is commonly overactive in many tumor types, resulted in a DNA repair defect similar to that seen in familial cancers. They subsequently showed that this "forced" DNA repair defect increased tumor sensitivity to PARP inhibitors. Because HER2 and EGFR are in the same family of proteins, Yang and colleagues theorized that HER2-targeted therapies might force a similar DNA repair defect in HER2-positive tumors, increasing their sensitivity to PARP inhibitors.

They found that HER2-positive breast cancer cell lines were indeed sensitive to PARP inhibitors, both in culture and when transplanted into mice.

"However, the surprise was that these HER2-positive tumors were sensitive to PARP inhibitors alone, independent of a DNA repair defect," Yang said. "This means that there may be other mechanisms, outside of DNA repair, that dictate the sensitivity of a tumor to PARP inhibitors."

The researchers hope to further map out the reason why HER2-positive tumors are sensitive to PARP inhibitors. If better defined, the knowledge could ultimately broaden the clinical application for PARP inhibitors.

"Our research suggested that inhibition of NF-kB signaling is a possible cause of this sensitivity, but there may be other determinants as well," Yang said. "If we are able to find the determinants of sensitivity, we may be able to extrapolate our effects to other tumor types."


'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Inhibitors of shuttle molecule show promise in acute leukemia
2. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
3. First targeted nanomedicine to enter human clinical studies
4. Clinical insight improves treatment with new lung cancer drug
5. Clinical news alert from the American Academy of Orthopaedic Surgeons
6. NYU Langone experts present research, clinical advances at neurosurgeons meeting
7. Kroenke honored for outstanding contributions in clinical research training
8. Awards celebrate clinical research that can improve health and alleviate suffering
9. Association for Psychological Science, SAGE launch Clinical Psychological Science
10. URMC clinical trial tests new regimen for hypertension
11. Analysis Finds Clinical Trials Often Small, of Poor Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Lebanon, Oregon (PRWEB) , ... February 11, 2016 ... ... Oregon campus participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February ... The Match Program places students into osteopathic graduate medical education positions across the ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Image ... business to a new market, and it’s the buildings of Nashville that will benefit. ... when I needed to relocate to Nashville, there was no question that I would ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, ... health, is pleased to announce the promotions of Allison Kelly to executive vice ... Catone to executive vice president of North American capital sales, and Wendy Oseas ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... motivational speaker, trainer and author Ray Clarke poses a question as a challenge ... . In his book, "Being in the Being" (published by Partridge Singapore), Clarke ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces ... Therapy Standards of Practice, to include vascular visualization as a standard practice. AccuVein ... share of the market, facilitates adherence to this standard with its easy to ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , February 11, 2016 F ... answers at the ... a world-leading provider of scientific, technical and medical information products and services, ... to evidence-based, peer reviewed clinical information via a mobile device. Elsevier designed ... ClinicalKey for Nursing. The new app is available in Android ...
(Date:2/11/2016)... spurred by a major "team investment" by Bruce Montgomery , one of this area,s most ... to CEO Leen Kawas , PhD. Photo ... ... ... Kawas said the round was intended to be ...
(Date:2/11/2016)... 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) ... at the 38th annual John A. Boswick , ... is being held February 14-18, 2016 in ... advancements in wound healing, burn care, and infection control, ... Zealand Burns Association, Academy of Physicians in Wound Care ...
Breaking Medicine Technology: